Bladder Cancer Clinical Research Trials

Duarte : City of Hope

A Randomized, Double-Blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients with Advanced Transitional Cell Carcinoma

Duarte : City of Hope

Bladder Cancer Database

Palo Alto : VA Palo Alto Health Care System

Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology

Stanford : Stanford University School of Medicine

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Denver : The Urology Center of Colorado

Phase 2, randomized, open label, parallel ARM study to evaluate the safety and efficacy of rAd-IFN/Syn 3 following intravesical administration in subjects with high grade, BCG refractory or relapsed non-muscle invasive bladder cancer.

Denver : The Urology Center of Colorado

Phase II, open-label study evaluating DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma.

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

Atlanta : The Emory Clinic

Hexvix Cystoscopy for Detection of Bladder Cancer

Chicago : The University of Chicago

Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit

Indianapolis : Indiana University Simon Cancer Center

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Baltimore : The Johns Hopkins Medical Institutions

Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Basking Ridge : Memoral Sloan Kettering Cancer Center

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Lake Success : Biomedical Research Alliance of New York

Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults

New Hyde Park : The Arthur Smith Institute for Urology

EN3348 As Compared With Mitomycin C in the Treatment of BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

New York : Memorial Sloan-Kettering Cancer Center

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

New York : Memorial Sloan Kettering Cancer Center

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

New York : Herbert Irving Pavillion 11th Floor

Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer

New York : Mount Sinai Medical Center

Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

New York : Memorial Sloan Kettering Cancer Center

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

New York : Mount Sinai Medical Center

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Rockville Centre : Memorial Sloan-Kettering Cancer Center at Mercy Medical Center

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Staten Island : Staten Island University Hospital

Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

A phase 3 international, multicenter, double-blind, placebo-controlled, randomized trial evaluating the efficacy and safety of multiple instillations of intravesical apaziquone vs. placebo in patients with low-intermediate risk non-muscle invasive bladder cancer (NMIBC). Clinical trial NCT01410565.

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Nashville : Sarah Cannon Research Institute

Safety Study of MGAH22 in HER2-positive Carcinomas

Houston : UT MD Anderson Cancer Center

Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors

Znojmo : Nemocnice Znojmo

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Essen : Kliniken Essen-Mitte - PS Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Homburg/Saar : Saarland University

Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer

Wiesbaden : Vivantes-Klinikum Neukoelln Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Chiba : Nippon kayaku Investigational site 101

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Fukuoka : Nippon Kayaku Investigational site 110

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Fukuoka : Nippon Kayaku Investigational site 111

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Hamamatsu : Nippon Kayaku Investigational site 104

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Kashihara : Nippon Kayaku Investigational site 107

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Kurashiki : Nippon Kayaku Investigational site 109

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Musashino : Nippon Kayaku Investigational site 102

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Nara : Nippon Kayaku Investigational site 106

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Okayama : Nippon Kayaku Investigational site 108

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Osakasayama : Nippon Kayaku Investigational site 105

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Yokosuka : Nippon Kayaku Investigational site 103

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Bundang : Handok Investigational site 203

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Daegu : Handok Investigational site 202

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Hwasun : Handok Investigational site 209

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Seoul : Seoul National University Hospital

Safety Study of MGAH22 in HER2-positive Carcinomas

Seoul : Handok Investigational site 201

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Seoul : Handok Investigational site 204

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Seoul : Handok Investigational site 207

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Seoul : Handok Investigational site 205

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Seoul : Handok Investigational site 206

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Yangsan : Handok Investigational site 208

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Maastricht : Academisch Ziekenhuis Maastricht Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Nieuwegein : St. Antonius Ziekenhuis Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Nijmegen : Department of Urology, UMC St. Radboud

Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB

Lublin : SPSK1 Klinika Hematologii

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Barcelona : H de La Santa Creu i Sant Pau Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Barcelona : Hospital Clinic i Provincial de Barcelona

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Elche- Alicante : HGU de Elche - General Universitario de Elche Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Madrid : Centro Integral Oncologico Clara Campal Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Madrid : Complejo Hospitalario de San Carlos Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Sabadell : Corporació Sanitaria Parc Taulí Updated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Genolier : IMO Clinique de Genolier

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Aberdeen : NHS Grampian - Aberdeen Royal Infirmary